Medtronic appoints Groetelaars, Jellison to Board, forms growth and operating committees.

Medtronic has appointed John Groetelaars and Bill Jellison as independent directors, forming new Growth and Operating committees to focus on strategic portfolio management, operational execution, and capital allocation. The company plans to host an Investor Day in 2026 and has initiated these initiatives following constructive engagement with Elliott Management. The moves aim to enhance shareholder value creation and sharpen the company's focus on its ongoing strategic priorities.

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, has taken significant steps to enhance its strategic focus and operational efficiency. The company announced the appointment of John Groetelaars and Bill Jellison as independent directors, effective immediately [1]. This move comes on the heels of constructive engagement with Elliott Management and is part of a broader initiative to create shareholder value.

Groetelaars and Jellison bring extensive experience in the medical technology industry. Groetelaars, who previously served as interim CEO at Dentsply Sirona and President & CEO at Hillrom, will contribute his global leadership experience across various medical device sectors [1]. Jellison, a former Vice President and Chief Financial Officer at Stryker Corporation, will provide deep financial expertise [1].

To align governance with existing management focus areas and workstreams, the Medtronic Board has formed two special committees: the Growth Committee and the Operating Committee. The Growth Committee will guide the evaluation and execution of growth-accretive tuck-in M&A, organic R&D investments, and potential divestitures, including the separation of the Diabetes business [1]. The Operating Committee will focus on optimizing operational performance, delivering margin expansion, and driving sustained earnings acceleration [1].

Chief Executive Officer and Chairman of the Board, Geoff Martha, will serve as the chair of both committees. The new directors, Groetelaars and Jellison, will also serve on one or both of the committees [1].

Martha stated, "We are at an exciting inflection point and in a period of strong momentum, with multiple growth drivers already delivering and additional breakthrough therapies set to launch in the months ahead. With the addition of these new Board members and the formation of these two new committees, we are accelerating our strategic growth priorities and advancing the simplification and optimization of our operations" [1].

The company plans to host an Investor Day in mid-calendar year 2026 to discuss the work of the Growth and Operating Committees, including Medtronic's go-forward strategic priorities and financial algorithm [1].

Elliott Partner Marc Steinberg commented, "Our decision to become one of Medtronic's largest investors was driven by our strong conviction that the company is entering a new chapter of exceptional value creation defined by accelerating growth, operational improvement and enhanced strategic clarity" [1].

Groetelaars and Jellison will be nominated to stand for election at Medtronic's 2025 Annual General Meeting of Shareholders [1].

References:
[1] https://news.medtronic.com/2025-08-19-Medtronic-announces-Board-appointments-and-shareholder-value-creation-initiatives-to-advance-strategic-priorities